Revenue (Tables)

9 Months Ended

Sep. 30, 2022

Disaggregation of Revenue [Abstract]

Disaggregation of Revenue [Table Text Block]

The following tables disaggregate our revenue from contracts with customers by component and geographic region (in millions). We have revised prior periods to conform to current year presentation:

	Three Months Ended September 30,
	2022						2021
Businesses	U.S.		Int'l		Total		U.S.		Int'l		Total
Endoscopy	$	342	$	217	$	559	$	306	$	227	$	533
Urology and Pelvic Health	315		118		433		275		109		384
Neuromodulation	173		48		221		175		46		221
MedSurg	830		383		1,213		756		382		1,138
Interventional Cardiology Therapies	190		359		549		193		341		534
Watchman	234		28		262		183		26		210
Cardiac Rhythm Management	338		181		519		312		199		512
Electrophysiology	73		75		148		32		55		86
Cardiology	836		643		1,479		720		622		1,342
Peripheral Interventions	269		210		479		250		202		452
Cardiovascular	1,104		853		1,958		970		824		1,794
Total Net Sales	$	1,934	$	1,236	$	3,170	$	1,726	$	1,206	$	2,932

	Nine Months Ended September 30,
	2022						2021
Businesses	U.S.		Int'l		Total		U.S.		Int'l		Total
Endoscopy	$	992	$	657	$	1,649	$	902	$	681	$	1,583
Urology and Pelvic Health	921		375		1,296		817		325		1,142
Neuromodulation	519		150		669		520		145		666
MedSurg	2,432		1,182		3,614		2,239		1,151		3,390
Interventional Cardiology Therapies	568		1,099		1,667		593		1,041		1,634
Watchman	662		76		738		524		72		596
Cardiac Rhythm Management	1,005		575		1,580		903		603		1,505
Electrophysiology	196		222		418		96		169		265
Cardiology	2,431		1,972		4,403		2,115		1,885		4,000
Peripheral Interventions	782		641		1,423		748		609		1,358
Cardiovascular	3,213		2,613		5,826		2,864		2,494		5,358
Specialty Pharmaceuticals	—		—		—		10		4		13
Total Net Sales	$	5,645	$	3,795	$	9,440	$	5,112	$	3,649	$	8,761

Refer to Note K- Segment Reporting for information on our reportable segments.

	Three Months Ended September 30,				Nine Months Ended September 30,
Regions	2022		2021		2022		2021
U.S.	$	1,934	$	1,726	$	5,645	$	5,103
Europe, Middle East and Africa	585		590		1,869		1,855
Asia-Pacific	532		517		1,579		1,511
Latin America and Canada	119		99		347		279
Medical Devices	3,170		2,932		9,440		8,748
U.S.	—		—		—		10
International	—		—		—		4
Specialty Pharmaceuticals	—		—		—		13
Total Net Sales	$	3,170	$	2,932	$	9,440	$	8,761
Emerging Markets(1)	$	454	$	354	$	1,271	$	1,031

(1)    We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, which currently includes the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Turkey and Vietnam.